Healthy
Conditions
Keywords
Glucagon-Like Peptide 2, GLP-2, GLP-2 (3-33), GLP-2 (1-33), Gastrointestinal Blood Flow, Superior Mesenteric Artery, Portal Vein
Brief summary
This project will describe the role of physiological levels of GLP-2 in regulating the blood flow to the intestines and the effect of the antagonist GLP-2(3-33) in blocking these effects of GLP-2.
Detailed description
Ten healthy participants will meet fasting and attend four randomized experimental days of MRI-scans of the abdomen. Each day will include subcutaneous injections of GLP-2 or saline and intravenous infusion of either the GLP-2 (3-33) antagonist or saline. The infusion start at timepoint -20, while the subcutaneous injection is given to timepoint 0 and the participant will lay in the scanner in one hour after injection. Eight MR-scans are done repeatedly to measure the blood flow in larger abdominal vessels and four blood samples are taken during the experimental day for analysis of GLP-2(1-33), GLP-2(3-33) and bone markers.
Interventions
OTHERSaline infusion
Saline/NaCl (9mg/ml) intravenous infusion
OTHERSaline injection
Saline/NaCl (9mg/ml) subcutaneous injection
OTHER1nmol antagonist infusion
GLP-2 (1-33)/GLP-2(3-33) 1 nmol/kg/min
OTHER4 nmol antagonist infusion
GLP-2 (1-33)/GLP-2 (3-33) 4 nmol/kg/min
OTHERAgonist injection
GLP-2(1-33) subcutaneous injection
Sponsors
Rigshospitalet, Denmark
University of Copenhagen
Study design
Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
BASIC_SCIENCE
Masking
SINGLE (Subject)
Intervention model description
Randomised, placebo-controlled, single-blinded, crossover-study
Eligibility
Sex/Gender
ALL
Age
18 Years to 70 Years
Healthy volunteers
Yes
Inclusion criteria
* Age 18-70 years * BMI 19-28 kg/m2
Exclusion criteria
* Chronic illness that affects the cardiovascular system or gastrointestinal tract * Treatment with medicine or supplements that cannot be paused for 12 hours * Intake of above 14 alcoholic drinks per week or substance abuse * Liver enzymes (ALAT) above 2 times normal values * Decreased kidney function (eGFR below 90 or creatinine levels over reference value) * Low blood percentage (hemoglobin below reference value) * Any condition or disease that the persons responsible for the study find would interfere with the participation of the study.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| SMA blood flow | 85 minutes | Blood flow in the superior mesenteric artery |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| PVblood flow | 85 minutes | Blood flow in the portal vein |
Countries
Denmark
Outcome results
None listed